New Mountain Capital, a growth-oriented investment firm with more than $37 billion in assets under management and Emmes, a global, tech-enabled full-service clinical research organisation (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, have formed a partnership to support and accelerate Emmes’ next phase of growth.
Affiliates of New Mountain will acquire the ownership interest of Behrman Capital, the majority investor in Emmes since March 2019, and the ownership interests of Emmes’ other investors. The transaction is expected to close in early July and terms were not disclosed.
Emmes provides its clients with expertise in biostatistics, technologies and dedicated service required to manage clinical research studies with the highest standards of quality. The company sits at the intersection of the public and private healthcare sectors with clients including biopharmaceutical companies, government agencies, foundations, academic institutions and other non-profit organisations.